U.S. markets close in 38 minutes

Vapotherm, Inc. (VAPO)

NYSE - NYSE Delayed Price. Currency in USD
0.5900+0.0325 (+5.83%)
As of 02:52PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close0.5575
Bid0.5900 x 2900
Ask0.6050 x 800
Day's Range0.5487 - 0.6050
52 Week Range0.4600 - 15.7800
Avg. Volume289,250
Market Cap27.254M
Beta (5Y Monthly)-1.08
PE Ratio (TTM)N/A
EPS (TTM)-3.6900
Earnings DateMay 02, 2023 - May 08, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.74
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VAPO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vapotherm, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/18/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • Business Wire

    Vapotherm Announces NYSE Continued Listing Standard Notice Related to Stock Price

    EXETER, N.H., March 17, 2023--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it was notified (the "Notice") on March 15, 2023 by the New York Stock Exchange, Inc. (the "NYSE") that the Company is not in compliance with the NYSE’s conti

  • Zacks

    Vapotherm (VAPO) Reports Q4 Loss, Tops Revenue Estimates

    Vapotherm (VAPO) delivered earnings and revenue surprises of 6.33% and 0.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Vapotherm Reports Fourth Quarter and Fiscal Year 2022 Financial Results

    EXETER, New Hampshire, February 23, 2023--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced fourth quarter and fiscal year 2022 financial results.